Genomic ETF Returns Soared on AI-Biotech Synergy

The ARK Genomic Revolution ETF gained 86% in 2026 as its primary holdings integrated AI with biological research.

Updated on Oct. 5, 2026 in Biotech

Isometric editorial illustration of a robotic biological synthesis arm, representing advancements in genetic and AI research infrastructure. — The ARK Genomic Revolution ETF reached an 86% return in 2026, bolstered by firms specializing in AI-integrated biological hardware and synthetic genetic material. AI Illustration. Upload story photo >

Live Poll

Is now a good time to sell high-growth tech stocks to lock in recent gains?

The ARK Genomic Revolution ETF has returned 86% in 2026, fueled largely by the massive growth of two core holdings: Twist Bioscience and 10x Genomics. These firms gained 495% and 473% respectively as they scaled services and hardware at the intersection of AI and biology.

Why it matters

This performance highlights the market's increasing valuation of tools that bridge biological research and artificial intelligence. These companies provide the essential hardware and synthetic data infrastructure required to train models on complex genomic datasets.

Twist Bioscience reported third-quarter revenue of $118.4 million with a 52.8% gross margin. 10x Genomics recently shipped its Atera instrument, which works alongside the company's new Sentira cloud analysis platform.

The players

ARK Genomic Revolution ETF

An exchange-traded fund focused on companies advancing CRISPR, gene therapy, and synthetic biology.

Twist Bioscience

A synthetic biology firm that manufactures custom DNA and develops antibody libraries for pharmaceutical and AI research.

10x Genomics

A developer of single-cell and spatial analysis instruments used to profile gene expression in human tissue samples.

The details

Twist Bioscience provides synthetic DNA—custom-manufactured genetic material—and antibody-testing services utilized in training artificial intelligence models. 10x Genomics produces specialized instruments designed to map gene activity within tissue, providing the foundational data that AI systems require for high-resolution biological analysis.

2025 year-end: Baseline used for stock price gains.
August 2026: Anthropic research utilized Twist and Adaptyv Bio services.
September 2026: 10x Genomics launched Atera hardware and the Sentira platform.
October 2, 2026: Date of the latest ARK holdings disclosure.
Early 2027: Expected paid launch for the 10x Sentira platform.

The Tech Race

The valuation gains reflect a competitive shift toward firms providing the data-rich input required for biological AI. This follows the industry-wide push to move beyond simple sequencing toward integrated platforms that combine instrument hardware with cloud-based inference.

These developments currently affect institutional researchers and lab environments by providing faster tools for gene activity mapping. While hardware availability for Atera is ongoing, individual researchers should monitor for the paid release of the Sentira cloud platform in early 2027.

The takeaway

The market is betting that the companies controlling the 'data-input' side of biology will capture significant value as AI models mature. Monitor the upcoming 2027 paid launch of 10x Genomics' Sentira platform to see if these high growth rates translate into sustained revenue growth.